44
Participants
Start Date
September 26, 2020
Primary Completion Date
March 31, 2022
Study Completion Date
July 28, 2022
LTI-01
single-chain urokinase plasminogen activator, scuPA
Placebo
normal saline
North Shore - Long Island Jewish Medical Center, Queens
The Pennsylvania State University, Hershey
University of Pennsylvania, Philadelphia
Temple University, Philadelphia
University of Maryland School of Medicine, Baltimore
Johns Hopkins University, Baltimore
INOVA, Fairfax
Virginia Commonwealth University, Richmond
University of North Carolina at Chapel Hill, Chapel Hill
Duke University, Durham
The University of Alabama at Birmingham, Birmingham
Vanderbilt Medical Center, Nashville
University of Mississippi Medical Center, Jackson
The Ohio State University, Columbus
University of Michigan, Ann Arbor
Medical College of Wisconsin, Milwaukee
Mayo Clinic, Rochester
Rush University Medical Center, Chicago
Washington University, St Louis
St. Luke's Health System, Kansas City
The University of Kansas Medical Center, Kansas City
CHI CUMC Bergan Mercy, Omaha
The University of Texas Southwestern Medical Center, Dallas
The University of Texas Health Science Center, Houston
University of Colorado, Aurora
University of Utah, Salt Lake City
University of California (UCLA), Los Angeles
UC San Diego Health Jacobs Medical Center, La Jolla
UC Davis Medical Group, Sacramento
Yale School of Medicine, New Haven
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Lahey Hospital and Medical Center, Burlington
Lead Sponsor
Rein Therapeutics
INDUSTRY